New Histone Deacetylase Inhibitors As Potential Therapeutic Tools for Advanced Prostate Carcinoma

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2008 Feb 13

PMID 18266964

Citations 9

Authors

S A Wedel

A Sparatore

P D Soldato

S-E Al-Batran

A Atmaca

E Juengel

L Hudak

D Jonas

R A Blaheta

Affiliations

Soon will be listed here.

Abstract

The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti-neoplastic effects in vitro may not be reached in tumour patients. In this study, we tested in vitro and in vivo effects of two VPA-derivatives (ACS2, ACS33) on pre-clinical prostate cancer models. PC3 and DU-145 prostate tumour cell lines were treated with various concentrations of ACS2 or ACS33 to perform in vitro cell proliferation 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and to evaluate tumour cell adhesion to endothelial cell monolayers. Analysis of acetylated histones H3 and H4 protein expression was performed by western blotting. In vivo tumour growth was conducted in subcutaneous xenograft mouse models. Tumour sections were assessed by immunohistochemistry for histone H3 acetylation and proliferation. ACS2 and ACS33 significantly up-regulated histone H3 and H4 acetylation in prostate cancer cell lines. In micromolar concentrations both compounds exerted growth arrest in PC3 and DU-145 cells and prevented tumour cell attachment to endothelium. In vivo, ACS33 inhibited the growth of PC3 in subcutaneous xenografts. Immunohistochemistry and western blotting confirmed increased histone H3 acetylation and reduced proliferation. ACS2 and ACS33 represent novel VPA derivatives with superior anti-tumoural activities, compared to the mother compound. This investigation lends support to the clinical testing of ACS2 or ACS33 for the treatment of prostate cancer.

Citing Articles

New sulfurated derivatives of cinnamic acids and rosmaricine as inhibitors of STAT3 and NF-κB transcription factors.

Gabriele E, Brambilla D, Ricci C, Regazzoni L, Taguchi K, Ferri N J Enzyme Inhib Med Chem. 2017; 32(1):1012-1028.

PMID: 28738705 PMC: 6009881. DOI: 10.1080/14756366.2017.1350658.

Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain.

Gabriele E, Ricci C, Meneghetti F, Ferri N, Asai A, Sparatore A J Enzyme Inhib Med Chem. 2017; 32(1):337-344.

PMID: 28097912 PMC: 6009886. DOI: 10.1080/14756366.2016.1252757.

Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L.

Ueki N, Wang W, Swenson C, McNaughton C, Sampson N, Hayman M Theranostics. 2016; 6(6):808-16.

PMID: 27162551 PMC: 4860889. DOI: 10.7150/thno.13826.

Regulators of gene expression as biomarkers for prostate cancer.

Willard S, Koochekpour S Am J Cancer Res. 2012; 2(6):620-57.

PMID: 23226612 PMC: 3512182.

Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.

Chou Y, Chaturvedi N, Ouyang S, Lin F, Kaushik D, Wang J Cancer Lett. 2011; 311(2):177-86.

PMID: 21862211 PMC: 3232184. DOI: 10.1016/j.canlet.2011.07.015.

References

Blaheta R, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B . Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer. 2007; 96(11):1699-706. PMC: 2359931. DOI: 10.1038/sj.bjc.6603777. View

Dashwood R, Ho E . Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol. 2007; 17(5):363-9. PMC: 2737738. DOI: 10.1016/j.semcancer.2007.04.001. View

Cinatl Jr J, Cinatl J, Driever P, Kotchetkov R, Pouckova P, Kornhuber B . Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs. 1998; 8(10):958-63. DOI: 10.1097/00001813-199711000-00007. View

Lu Q, Yang Y, Chen C, Davis M, Byrd J, Etherton M . Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004; 47(2):467-74. DOI: 10.1021/jm0303655. View

Munster P, Marchion D, Bicaku E, Schmitt M, Lee J, DeConti R . Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007; 25(15):1979-85. DOI: 10.1200/JCO.2006.08.6165. View

LEA M, Randolph V, Lee J, Desbordes C . Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int J Cancer. 2001; 92(6):784-9. DOI: 10.1002/ijc.1277. View

Phiel C, Zhang F, Huang E, Guenther M, Lazar M, Klein P . Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276(39):36734-41. DOI: 10.1074/jbc.M101287200. View

Michaelis M, Michaelis U, Fleming I, Suhan T, Cinatl J, Blaheta R . Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004; 65(3):520-7. DOI: 10.1124/mol.65.3.520. View

Reddy B . Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Prev Med. 1996; 25(1):48-50. DOI: 10.1006/pmed.1996.0017. View

10.

Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V . Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem. 2004; 48(3):273-90. View

11.

Blaheta R, Cinatl Jr J . Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002; 22(5):492-511. DOI: 10.1002/med.10017. View

12.

Nau H, Hauck R, Ehlers K . Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol. 1991; 69(5):310-21. DOI: 10.1111/j.1600-0773.1991.tb01303.x. View

13.

Reddy B, Kawamori T, Lubet R, Steele V, Kelloff G, Rao C . Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis. 1999; 20(8):1645-8. DOI: 10.1093/carcin/20.8.1645. View

14.

Isenberg J, Jia Y, Field L, Ridnour L, Sparatore A, Del Soldato P . Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol. 2007; 151(1):63-72. PMC: 2012973. DOI: 10.1038/sj.bjp.0707198. View

15.

Gao D, Xia Q, Lv J, Zhang H . Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol. 2007; 14(9):838-45. DOI: 10.1111/j.1442-2042.2007.01823.x. View

16.

Xia Q, Sung J, Chowdhury W, Chen C, Hoti N, Shabbeer S . Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006; 66(14):7237-44. DOI: 10.1158/0008-5472.CAN-05-0487. View

17.

Atmaca A, Al-Batran S, Maurer A, Neumann A, Heinzel T, Hentsch B . Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer. 2007; 97(2):177-82. PMC: 2360302. DOI: 10.1038/sj.bjc.6603851. View

18.

Halkidou K, Gaughan L, Cook S, Leung H, Neal D, Robson C . Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004; 59(2):177-89. DOI: 10.1002/pros.20022. View

19.

Eyal S, Yagen B, Shimshoni J, Bialer M . Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol. 2005; 69(10):1501-8. DOI: 10.1016/j.bcp.2005.02.012. View

20.

Ruggeri B, Robinson C, Angeles T, Wilkinson 4th J, Clapper M . The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res. 2002; 8(1):267-74. View